Related Experiment Videos
Campath and renal transplant rejection
Philip G Thomas1, Kanae Ishihara, Smita Vaidya
1Department of Surgery, The University of Texas Medical Branch, Galveston, TX 77555, USA. pgthomas@utmb.edu
Clinical Transplantation
|November 2, 2004
Summary
Treatment for acute vascular rejection after kidney transplants lacks clear guidelines. A patient treated with plasmapheresis, immunoglobulin, and Campath experienced recurrence, graft loss, and post-transplant lymphoma.
Area of Science:
- Nephrology
- Transplantation Immunology
Background:
- Acute vascular rejection is a significant complication following renal transplantation.
- Current treatment protocols for this condition remain undefined.
Observation:
- This case report details a single patient's experience with acute vascular rejection post-kidney transplant.
- The patient received a treatment regimen including plasmapheresis, immunoglobulin, and Campath.
Findings:
- The patient demonstrated an initial positive response to the treatment.
- However, the rejection recurred, leading to irreversible graft loss.
- Furthermore, the patient developed post-transplant lymphoproliferative disorder (PTLD).
Implications:
- This case highlights the challenges in managing acute vascular rejection in renal transplant recipients.
- The observed recurrence and subsequent complications underscore the need for refined treatment strategies.
- Further research is warranted to establish effective and safe therapeutic guidelines to prevent graft loss and PTLD.